Advertisement

Der Urologe

pp 1–9 | Cite as

Therapie des metastasierten Prostatakarzinoms im Wandel – neue Daten und offene Fragen

  • P. AlbersEmail author
  • M. Bögemann
  • S. Machtens
  • A. S. Merseburger
  • M. Schostak
  • T. Steuber
  • C. Wülfing
  • M. De Santis
Originalien

Zusammenfassung

Die Taxan-basierte Chemotherapie und die gegen den Androgenrezeptor gerichteten Substanzen („androgen receptor-targeted agent“, ARTA) haben die therapeutischen Möglichkeiten beim metastasierten Prostatakarzinom (mPC) deutlich erweitert und bieten den Patienten die Chance, länger zu überleben. Die Therapiesequenz von ARTA und Taxanen kann Einfluss auf die Prognose haben und muss individuell entschieden werden. Ziel der vorliegenden Publikation ist es, eine Orientierungshilfe für den klinischen Alltag zu geben und Kriterien zu erarbeiten, die bei der individuellen Therapieentscheidung berücksichtigt werden können. Im Fokus stehen das metastasierte hormonnaive PC, die Behandlung oligometastasierter Patienten sowie das nichtmetastasierte und das metastasierte kastrationsresistente PC.

Schlüsselwörter

Androgenrezeptor Kastrationsnaives Prostatakarzinom Chemotherapie Oligometastasierung Systemische Therapie 

Changes in the treatment of metastatic prostate cancer—new data and open questions

Abstract

The availability of taxane-based chemotherapy and androgen-receptor-targeted agents (ARTAs) have significantly broadened the therapeutic options for patients with metastatic prostate cancer and may also result in longer patient survival. The therapeutic sequence of ARTAs and taxanes may influence outcome and therefore decisions should be made on an individual basis. This article provides guidance for therapeutic decision-making in daily clinical practice by working out criteria that can be used to support individual therapeutic decisions. The focus is on metastatic castration-naive prostate cancer, oligometastatic disease as well as non-metastatic and metastatic castration-resistant prostate cancer.

Keywords

Androgen receptor Prostatic neoplasms, castration-naive Chemotherapy Oligometastases Systemic therapy 

Notes

Dieses Manuskript wurde mit Unterstützung der Firma Sanofi erstellt.

Einhaltung ethischer Richtlinien

Interessenkonflikt

P. Albers: Sanofi, MSD, Roche. M. Bögemann: Sanofi, Janssen, Astellas, Bayer, Abx. M. Schostak: Forschungsförderung durch MSD, BMS, Astra Zeneca, Sanofi, Roche, Novartis, Janssen, Reisekostenerstattungen durch MSD, BMS, Astra Zeneca, Sanofi, Roche, Novartis, Janssen, Berater: EDAP-TMS. C. Wülfing: Teilnehmer und Referent bei diversen Advisory Boards zum Prostatakarzinom, Sanofi, Janssen, Astellas. M. De Santis: Honorare: Amgen, Astellas, AstraZeneca, Basilea, Bayer, Bioclin, BMS, EISAI, ESSA, Ferring, Ipsen, Janssen, MSD, Merck, Novartis, Orion, Pfizer, Pierre Fabre Oncology, Roche, Sandoz, Sanofi, SeaGen, Takeda; Beratertätigkeit Amgen, Astellas, AstraZeneca, Basilea, Bayer, Bioclin, BMS, EISAI, ESSA, Ferring, Ipsen, Janssen, MSD, Merck, Novartis, Orion, Pfizer, Pierre Fabre Oncology, Roche, Sandoz, Sanofi, SeaGen, Takeda. S. Machtens, A.S. Merseburger und T. Steuber geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Literatur

  1. 1.
    Almeida DVP, de Oliviera CZ, Mariano RC et al (2018) Non-metastatic castration-resistant prostate cancer: meta-analysis of efficacy and safety with hormonal agents apalutumide and enzalutamide. Ann Oncol 29(suppl_8):viii271–viii302.  https://doi.org/10.1093/annonc/mdy284 CrossRefGoogle Scholar
  2. 2.
    Angelergues A, Maillet D, Flechon A et al (2014) Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 32(suppl 4):282aCrossRefGoogle Scholar
  3. 3.
    Angelergues A, Efstathiou E, Gyftaki R et al (2018) Results of the FLAC European database of metastatic castration-resistant prostate cancer patients treated with docetaxel, cabazitaxel, and androgen receptor-targeted agents. Clin Genitourin Cancer 16(4):e777–e784CrossRefGoogle Scholar
  4. 4.
    Attard G, Borre M, Gurney H et al (2018) Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment. J Clin Oncol 36(25):2639–2646CrossRefGoogle Scholar
  5. 5.
    Boevé LMS, Hulshof MCCM, Vis AN et al (2018) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol.  https://doi.org/10.1016/j.eururo.2018.09.008 CrossRefPubMedGoogle Scholar
  6. 6.
    Caffo O, Bria E, Giorgi UD et al (2017) Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: final analysis from a multicenter Italian study. J Clin Oncol 35(suppl 15):5030CrossRefGoogle Scholar
  7. 7.
    Carles J, Pichler A, Korunkova H et al (2018) An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA). BJU Int.  https://doi.org/10.1111/bju.14509 CrossRefPubMedGoogle Scholar
  8. 8.
    Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 65(6):1058–1066CrossRefGoogle Scholar
  9. 9.
    De Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154CrossRefGoogle Scholar
  10. 10.
    de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995–2005CrossRefGoogle Scholar
  11. 11.
    Deutsches Register klinischer Studien. DRKS-ID der g‑RAMPP-Studie: DRKS00008770. www.drks.de/drks_web/ oder www.martini-klinik.de/fuer-arzte/studien/studienuebersicht/g-rampp-studie
  12. 12.
    EAU-Empfehlungen. https://uroweb.org/individual-guidelines/oncology-guidelines/. Zugegriffen: 07. Mai 2019
  13. 13.
    Eisenberger M, Hardy-Bessard A‑C, Kim CS (2017) Phase III study comparing a reduced dose of cabazitaxel (20 mg/m2) and the currently approved dose (25 mg/m2) in postdocetaxel patients with metastatic castration-resistant prostate cancer—PROSELICA. J Clin Oncol 35(28):3198–3206CrossRefGoogle Scholar
  14. 14.
    Fizazi K, Scher HI, Molina AM et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised double-blind placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992CrossRefGoogle Scholar
  15. 15.
    Fiazi K, Delva R, Gravis G et al (2017) Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC): results from the CABADOC randomized trial. Ann Oncol 28(suppl 5):v269–v294.  https://doi.org/10.1093/annonc/mdx370.019 CrossRefGoogle Scholar
  16. 16.
    Fizazi K, Tran NP, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castrations-sensitive prostate cancer. N Engl J Med 377:352–360CrossRefGoogle Scholar
  17. 17.
    Fizazi K, Tran N, Fein L et al (2019) Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HRmCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). ASCO GU. J Clin Oncol 37(suppl 7):141aCrossRefGoogle Scholar
  18. 18.
    Fizazi K, Shore N, Tammela TL et al (2019) Darolutamide in nonmetastatic, castration-resistant prostata cancer. N Engl J Med 380(13):1235–1246CrossRefGoogle Scholar
  19. 19.
    Gratzke C, Engel J, Stief CG (2014) Role of radical prostatectomy in metastatic prostate cancer. Data from the munich cancer registry. Eur Urol 66(3):602–603CrossRefGoogle Scholar
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
    Hussain M, Fizazi K, Saad F et al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378(36):2465–2474CrossRefGoogle Scholar
  25. 25.
    James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage platform randomised controlled trial. Lancet 387:1163–1177CrossRefGoogle Scholar
  26. 26.
    James ND, de Bono JS, Spears MR et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338–351CrossRefGoogle Scholar
  27. 27.
    Kellokumpu-Lehtinen P‑L, Harmenberg U, Joensuu T et al (2013) 2‑Weekly versus 3‑weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 14:117–124CrossRefGoogle Scholar
  28. 28.
    Khalaf D (2018) Phase 2 randomized cross-over trial of abiraterone vs enzalutamide for patients with mCPRC: results for 2nd-line therapy. J Clin Oncol 36(suppl 15):5015aCrossRefGoogle Scholar
  29. 29.
    Koo CH et al (2019) Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio. World J Urol.  https://doi.org/10.1007/s00345-019-02658-1 CrossRefPubMedGoogle Scholar
  30. 30.
    Kyriakopoulos C, Chen YH, Carducci MA et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 36(11):1080–1087.  https://doi.org/10.1200/JCO.2017.75.3657 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Lavaud P, Gravis G, Foulon S et al (2018) Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-naïve prostate cancer in the GETUG-AFU 15 phase 3 trial. Eur Urol 73(5):696–703CrossRefGoogle Scholar
  32. 32.
    Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.0, 2018, AWMF Registernummer: 043/022OL, http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/. Zugegriffen: 15. Jan. 2019
  33. 33.
    Maines F, Caffo O, Veccia A et al (2015) Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol 96:498–506CrossRefGoogle Scholar
  34. 34.
    Maroto P, Solsona E, Gallardo E et al (2016) Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer. Crit Rev Oncol Hematol 100:127–136CrossRefGoogle Scholar
  35. 35.
    Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36(5):446–453CrossRefGoogle Scholar
  36. 36.
    Parini V, Goyal R, Poropatich K, Yang XJ (2014) Neuroendocrine differentiation of prostata cancer: a review. Am J Clin Exp Urol 2(4):273–285Google Scholar
  37. 37.
    Parker CC, James Brawley NDCD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet.  https://doi.org/10.1016/S0140-6736(18)32486-3 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Pezaro CJ, Omlin A, Lorente D et al (2014) Visceral disease in castration-resistant prostate cancer. Eur Urol 65:270–273CrossRefGoogle Scholar
  39. 39.
    Rusthoven CG, Jones BL, Flaig TW et al (2016) Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol 34(24):2335–2342Google Scholar
  40. 40.
    Scher HI, Fizazi K, Saad F et al (2012) Increased survival with Enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197CrossRefGoogle Scholar
  41. 41.
    Schostak M, König F, Bögemann M et al (2018) Advanced Prostate Cancer Consensus Conference 2017: discussion of the recommendations for diagnosis and treatment of metastatic prostate cancer by a German panel of experts. Urologe 57(7):813–820CrossRefGoogle Scholar
  42. 42.
    Smith EJ, Saad F, Chowdhury S et al (2018) SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol 36(suppl 6):161aGoogle Scholar
  43. 43.
    Smith MR, Saad F, Oudard S et al (2013) Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 31(30):3800–3806CrossRefGoogle Scholar
  44. 44.
    Smith MR, Saad F, Chowdhury S et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15):1408–1418CrossRefGoogle Scholar
  45. 45.
    Smith M, Parker C, Saad F et al (2019) Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(3):408–419.  https://doi.org/10.1016/S1470-2045(18)30860-X CrossRefPubMedGoogle Scholar
  46. 46.
    Sooriakumaran P, Nyberg T, Akre O et al (2017) Survival among men at high risk of disseminated prostate cancer receiving initial locally directed radical treatment or initial androgen deprivation therapy. Eur Urol 72(3):345–351CrossRefGoogle Scholar
  47. 47.
    Steuber T, Berg KD, Roder MA et al (2017) Does Cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume Bone metastasis? Results from a prospective case-control study. Eur Urol Focus 3(6):646–649CrossRefGoogle Scholar
  48. 48.
    Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373(8):737–746CrossRefGoogle Scholar
  49. 49.
    Tannock IF, de Wit R, Berry W et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512CrossRefGoogle Scholar
  50. 50.
    Tu X, Chang T, Nie L et al (2019) Neuroendocrine carcinoma of the prostate: a sytematic review and pooled analysis. Urol Int 9:1–8.  https://doi.org/10.1159/000499883 CrossRefGoogle Scholar
  51. 51.
    Wang HAT, Yao YH, Li BG et al (2014) Neuroendocrine prostate cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis—a systematic review and pooled analysis. J Clin Oncol 32(30):3383–3390CrossRefGoogle Scholar
  52. 52.
    BfArm. Rote Hand-Mitteilung. www.bfarm.de/SharedDocs/Risikoinformationen. Zugegriffen: 22. Febr. 2019

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • P. Albers
    • 1
    Email author
  • M. Bögemann
    • 2
  • S. Machtens
    • 3
  • A. S. Merseburger
    • 4
  • M. Schostak
    • 5
  • T. Steuber
    • 6
  • C. Wülfing
    • 7
  • M. De Santis
    • 8
  1. 1.Klinik für Urologie und Universitätstumorzentrum, Comprehensive Cancer CenterUniversitätsklinikum, Medizinische Fakultät Heinrich-Heine-Universität, DüsseldorfDüsseldorfDeutschland
  2. 2.Klinik für Urologie und KinderurologieUniversitätsklinikum MünsterMünsterDeutschland
  3. 3.Klinik für Urologie und Kinderurologie, GFO Kliniken Rhein Berg, BetriebsstätteMarien-KrankenhausBergisch GladbachDeutschland
  4. 4.Klinik für Urologie, Campus LübeckUniversitätsklinikum Schleswig-HolsteinLübeckDeutschland
  5. 5.Klinik für Urologie und KinderurologieUniversitätsklinik MagdeburgMagdeburgDeutschland
  6. 6.Martini-Klinik, ProstatakrebszentrumUniversitätsklinikum Hamburg-EppendorfHamburgDeutschland
  7. 7.Abteilung für UrologieAsklepios Klinik AltonaHamburgDeutschland
  8. 8.Klinik für Urologie, Interdisziplinäre Uro-OnkologieCharité – Universitätsmedizin BerlinBerlinDeutschland

Personalised recommendations